COX-2 expression in uterine carcinosarcoma

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 1, 2010, Pages 120-125

  Menczer, Joseph ^a   Schreiber, Letizia ^b   Sukmanov, Oleg ^b   Kravtsov, Vladimir ^b   Berger, Esther ^b   Golan, Abraham ^a   Levy, Tally ^a  

^a Gynecologic Oncology Unit   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

COX 2 expression; Prognostic factors; Survival; Uterine carcinosarcoma

Indexed keywords

CYCLOOXYGENASE 2; PARAFFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROSCOPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; TISSUE SECTION; UTERINE CARCINOSARCOMA; UTERUS CARCINOMA; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PARAFFIN EMBEDDING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 73649128007     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016340903342006     Document Type: Article

References (24)

1. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
2. Hinz B, Brune K. Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther. 2002;300:367-375
3. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al Expression of cyclooxygenase 1 and -2 in human colorectal cancer. Cancer Res. 1995;55:3785-3789
4. Denkert C, Winzer KJ, Hauptman S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer. 2004;4:428-433
5. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008;14:8221-8227
6. Munkarah A, Ali-Fehmi R. COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol. 2005;17:49-53.
7. Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E.COX- 2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol. 2007;104:320-325
8. Li W, Xu RJ, Zhang HH, Jiang LH. Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma. Int J Gynecol Cancer. 2006;16:1673-1678
9. Khunamornpong S, Settakorn J, Sukpan K, Srisomboon J, Ruangvejvorachai P, Thorner PS, et al. Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis. Gynecol Oncol. 2009;112:241-247
10. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, et al. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol. 2008;110:445-451
11. Yoshida A, Sarian LO, Andrade LA, Pignataro F, Pinto GA, Derchain SF, et al. Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Int J Gynecol Cancer. 2007;17:607-614
12. Lee JS, Choi YD, Lee JH, Nam JH, Choi C, Lee MC, et al. Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression. Int J Gynecol Cancer. 2006;16: 247-253
13. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Cosio S, et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases, Eur J Gynecol. Oncol. 2002;23:295-299
14. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I carcinosarcoma. Am J Surg Path. 2007;31:1653-1661
15. Matsumoto Y, Ishiko O, Sumi T, Yoshida H, Deguchi M, Nakagawa E, et al. Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions. Oncol Rep. 2001;8:1225-1227
16. Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, et al. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol. 2005;96:159-167
17. Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P, et al. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007;105:138-144
18. Semczuk A, Scomra D, Chyzynska M, Szewczuk W, Olcha P, Korobowicz E. Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report. Pathol Res Pract. 2008;204:203-207
19. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002;12:687-690
20. Orejuela FJ, Ramondetta LM, Smith J, Brown J, Lemos LB, Li Y, et al. Estrogen and progesterone receptors and cyclooxygenase- 2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol Oncol. 2005;97:483-488
21. Uotila PJ, Erkkola RU, Klemi PJ. The expression of cyclooxygenase- 1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann Med. 2002;34:428-433
22. Abargel A, Avinoach I, Kravtsov V Boaz M, Glezerman M, Menczer J. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma. Int J Gynecol Cancer. 2004;14:354-359
23. Bamberger AM, Riethdorf L, Milde-Langosch K, Bamberger CM, Thuneke I, Erdmann I, et al. Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Virchows Arch. 1999;434:423-428
24. Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs. 2007;67:821-845